CA-TERIDION
23.5.2019 14:02:12 CEST | Business Wire | Press release
Teridion , the company delivering the only global public cloud-based WAN service , today announced its deep integration with Cisco Meraki MX Security and SD-WAN appliances. The combined solution is a bold new approach to branch networking, delivering the industry-leading Auto VPN and SD-WAN capabilities of Cisco Meraki’s MX appliances with Teridion’s high throughput and low latency public cloud-based WAN service.
For the first time, enterprises can take advantage of a WAN solution that has visibility and control of first, middle, and last mile of the Internet and extends SD-WAN and WAN acceleration beyond enterprise sites to include SaaS applications and enterprise cloud workloads across multiple public cloud providers. Today’s announcement highlights the new, seamless network level integration between Teridion’s high performance cloud WAN service and Cisco Meraki’s easy-to-use Auto VPN routing and high availability capabilities. Enterprise of all sizes can expect real-time applications such as voice and video to see latency improvements of up to 30 percent and file transfer throughput increases of up to 500 percent. As always, the Cisco Meraki and Teridion solution is secured with Cisco’s market-leading security capabilities and managed in the cloud.
The Teridion cloud WAN service is a simple, snap-in integration with Cisco Meraki MX enterprise security and SD-WAN appliances that brings carrier grade Internet and WAN performance to broadband and dedicated Internet access connections. Teridion is available at a fraction of the cost of carrier circuits, and is backed with an SLA. Partners that offer the combined Cisco Meraki and Teridion solution will be able to engage more opportunities and offer a compelling new service to their installed base.
“This news is tremendous validation for the differentiated WAN offering we launched late last year,” said Pejman Roshan, VP of Products and Marketing for Teridion. “We have been working closely with Cisco Meraki on this deep integration, and together the combined solution makes it easy to deploy a secure and high performance WAN that is 100-percent cloud managed. Together, Cisco Meraki and Teridion enable businesses with regional, nationwide, or global WANs to drastically improve the performance of business critical applications, whether they are hosted in corporate data centers, SaaS applications, or deployed across various cloud providers.”
“As enterprises prepare for a cloud-ready application environment, they are laser focused on providing the best application performance for staff and customers in remote locations and branch offices,” said Raviv Levi, director of product management at Cisco Meraki. “The combined Cisco Meraki and Teridion solution offers rich SD-WAN and security capabilities at the WAN edge that are tightly integrated with a high performance and cost-effective WAN service delivered over cost-effective broadband or dedicated Internet access. This brings better reliability and consistency to the enterprise WAN across multiple sites, as well as high performance access to all SaaS applications and cloud workloads.”
Teridion also announced today the general availability of Teridion for Enterprise, the industry’s first solution that eliminates the reliability and performance gap introduced by the reliance on the public Internet middle-mile and exposed by the massive shifts to the cloud and SD-WAN. By tightly integrating with a leading SD-WAN solution such as the Cisco Meraki SD-WAN, Teridion unites centralized cloud management, enterprise-grade security, and ultra-fast WAN performance in a single, tightly integrated offering. As a result, enterprises leverage a solution that is optimized for delivery performance, reliability, control, and visibility end to end across the public Internet.
Teridion’s public cloud-based WAN service is powered by Teridion Curated Routing , an innovative and cloud native approach to routing that draws on the power of deep learning and brings hierarchical and centralized routing to enterprise networking. Teridion Curated Routing radically improves WAN, application, and SaaS performance. Originally launched delivering interoperability with today’s most popular SD-WAN offerings, today’s announcement marks the first deep, end-to-end integration with a leading SD-WAN solution.
Learn more about Teridion’s deep integration with Cisco Meraki in the Cisco Meraki Marketplace at https://apps.meraki.io/details/teridion-for-enterprise/ , or at teridion.com/meraki .
Availability and Pricing
Teridion for Cisco Meraki is available today from authorized Teridion resellers. Pricing starts at $50 per site per month. More details about how to buy can be found at https://www.teridion.com/meraki .
About Teridion
Founded in 2013, Teridion enables faster and more reliable Internet with Teridion Curated Routing, radically improving Internet performance up to 2X - 20X, anywhere in the world. Teridion for Enterprise combines the performance, reliability, and SLAs of legacy WAN technologies such as MPLS with the agility and elastic scalability of the cloud. The company is backed by leading venture investors including Jerusalem Venture Partners, Magma Venture Partners and Singtel Innov8, and is relied on by leading SaaS providers such as Atlassian, Box, Egnyte, Merrill Corp., and many others. Teridion is headquartered in San Francisco, with international offices in Petah Tikva, Israel. For more information, visit www.teridion.com or email info@teridion.com .
Teridion is a registered trademark of Teridion in the United States and other countries. All rights reserved. All other company and product names are either trademarks or registered trademarks of their respective companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190523005161/en/
Contact:
Dan Spalding dspalding@teridion.com (408) 960-9297
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom